Frazier Life Sciences II completes $75M IPO
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Frazier Life Sciences Acquisition Corp. II (FLSC) reported a net loss of $112,569 from its August 7, 2026 inception through September 30, 2026, all from formation, general and administrative expenses, and no revenue. As of September 30, cash was $162,393 and the working capital deficit was $362,268. After quarter-end, FLSC completed its IPO on October 15, selling 7,500,000 public shares at $10.00 each for $75,000,000 in gross proceeds; $75,000,000 was deposited in the trust account. A concurrent private placement generated $3,000,000 in gross proceeds.
On October 13, FLSC entered a forward purchase agreement with Frazier Life Sciences Public Fund, L.P., an affiliate of its sponsor. The agreement provides for a minimum purchase of 2,500,000 shares for $25,000,000 at a business-combination closing, subject to the fund’s investment committee approval before FLSC enters a definitive agreement. FLSC has not selected a business-combination target or engaged in substantive discussions. It has 24 months from the IPO closing to complete a combination; management determined it has sufficient funds for working capital needs within one year of the financial statement’s issuance.
Filing Explained
Founder conversion may add Class A shares at closing; the three-million-dollar underwriting fee is due only if a business combination closes.
Frazier Life Sciences Acquisition Corp. II reports that its IPO is complete but it has not selected a business-combination target; as of
The underwriter’s deferred
Key Figures
Key Terms
blank check company technical
Business Combination financial
Trust Account financial
forward purchase agreement financial
working capital deficit financial
deferred underwriting commissions financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did FLSC raise in its IPO and private placement?
Has FLSC selected a business-combination target?
What are the terms of FLSC’s forward purchase agreement?
How long does FLSC have to complete a business combination?
AI-generated analysis. How Rhea-AI works. Not financial advice.
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
CA |
||
(Address of principal executive offices) |
(Zip Code) | |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | ☒ | |||||
| ☒ | ||||||
FRAZIER LIFE SCIENCES ACQUISITION CORP. II
FORM 10-Q
FOR THE PERIOD ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
| Part I. | Financial Information |
1 | ||
| Item 1. | Financial Statements (Unaudited) |
1 | ||
| Condensed Unaudited Balance Sheet as of September 30, 2026 |
1 | |||
| Condensed Unaudited Statement of Operations for the Period from August 7, 2026 (Inception) through September 30, 2026 | 2 | |||
| Condensed Unaudited Statement of Changes in Shareholders’ Deficit for the Period from August 7, 2026 (Inception) through September 30, 2026 | 3 | |||
| Condensed Unaudited Statement of Cash Flows for the Period from August 7, 2026 (Inception) through September 30, 2026 | 4 | |||
| Notes to Condensed Unaudited Financial Statements |
5 | |||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
15 | ||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
17 | ||
| Item 4. | Controls and Procedures |
17 | ||
| Part II | Other Information |
18 | ||
| Item 1. | Legal Proceedings |
18 | ||
| Item 1A. | Risk Factors |
18 | ||
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |
18 | ||
| Item 3. | Defaults upon Senior Securities |
19 | ||
| Item 4. | Mine Safety Disclosures |
19 | ||
| Item 5. | Other Information |
19 | ||
| Item 6. | Exhibits |
20 | ||
| Signatures | 21 | |||
i
ASSETS |
||||
Current assets: |
||||
Cash |
$ | |||
Total Current Assets |
||||
Deferred offering costs |
||||
Total Assets |
$ |
|||
LIABILITIES AND SHAREHOLDERS’ DEFICIT |
||||
Current liabilities: |
||||
Accounts payable |
$ | |||
Accrued expenses |
||||
Accrued offering costs |
||||
Promissory note - Sponsor |
||||
Total Current Liabilities |
||||
Commitments and Contingencies (Note 5) |
||||
SHAREHOLDERS’ DEFICIT |
||||
Shareholders’ Deficit |
||||
Preference shares, $ |
||||
Class A ordinary shares, $ |
||||
Class B ordinary shares, $ |
||||
Additional paid-in-capital |
||||
Accumulated deficit |
( |
) | ||
Total Shareholders’ Deficit |
( |
) | ||
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
$ |
|||
General, formation and administrative expenses |
$ | |||
Net loss |
$ | ( |
) | |
Basic and diluted net loss per ordinary share |
$ | ( |
) | |
Weighted average ordinary shares outstanding, basic and diluted |
||||
Class B Ordinary Shares |
Additional Paid-In Capital |
Accumulated Deficit |
Total Shareholders’ Deficit |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance as of August 7, 2026 (Inception) |
$ | $ | $ | $ | ||||||||||||||||
Issuance of Class B ordinary shares to Sponsor |
— | |||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
Balance as of September 30, 2026 |
$ | $ | $ | ( |
) | $ | ( |
) | ||||||||||||
Cash Flows from Operating Activities: |
||||
Net loss |
$ | ( |
) | |
Changes in operating liabilities |
||||
Accounts payable and accrued expenses |
||||
Net cash used in operating activities |
$ | ( |
) | |
Cash Flows from Financing Activities |
||||
Proceeds from issuance of Class B ordinary shares to Sponsor |
$ | |||
Proceeds from Promissory Note-Sponsor |
||||
Payment of deferred offering costs |
( |
) | ||
Net cash provided by financing activities |
$ | |||
Net Change in Cash |
||||
Cash – beginning of the period |
||||
Cash – end of the period |
$ | |||
Supplemental disclosure of non-cash investing and financing activities: |
||||
Offering costs included in accounts payable |
$ | |||
Offering costs included in accrued offering expenses |
$ |
Period From August 7, 2026 (Inception) to September 30, 2026 |
||||
General, formation and administrative expenses |
$ | |||
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings. References to the “Company”, “us,” “our,” or “we” refer to Frazier Life Sciences Acquisition Corp. II. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes herein.
Overview
We are a blank check company incorporated on August 7, 2026, as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We intend to effectuate our business combination using the cash from the Initial Public Offering and the sale of the private placement shares, our shares, debt or a combination of cash, equity and debt. We cannot assure you that our plans to complete a Business Combination will be successful.
Results of Operations and Known Trends or Future Events
We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities and activities related to the Initial Public Offering. Following the Initial Public Offering, we will not generate any operating revenues until after completion of our business combination at the earliest. We will generate non-operating income in the form of interest income on cash and cash equivalents derived from the Initial Public Offering and sale of private placement shares. Since the completion of the Initial Public Offering, we expect to incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. We expect our expenses to increase substantially after the closing of the Initial Public Offering.
For the period from August 7, 2026 (inception) through September 30, 2026, we had a net loss of $112,569, which consisted entirely of formation, general and administrative expenses of $112,569. We did not generate any revenues during this period. We did not have any assets held in the Trust Account as of September 30, 2026, as the Initial Public Offering closed on October 15, 2026, which was subsequent to the balance sheet date.
Liquidity and Capital Resources
As indicated in the accompanying financial statements, as of September 30, 2026, we had cash of $162,393 and a working capital deficit of $362,268. Further, we expect to incur significant costs in the pursuit of our business combination. We cannot assure you that our plans to complete our business combination will be successful. Subsequent to the end of the quarterly period covered by this Quarterly Report on October 15, 2026, the Company consummated its initial public offering of 7,500,000 shares of its Class A ordinary shares, par value $0.0001 per share (each, a “Public Share” and collectively, the “Public Shares”) at $10.00 per Public Share generating gross proceeds of $75,000,000 and incurring offering costs of $4,111,319, inclusive of $3,000,000 in deferred underwriting commissions, $750,000 of upfront underwriting discounts and $361,319 of other offering costs.
15
Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) of 300,000 Class A ordinary shares (the “Private Placement Shares”), generating gross proceeds of $3,000,000.
Prior to the closing of the Initial Public Offering our liquidity needs have been satisfied through a payment of $25,000 from our sponsor to cover certain expenses in exchange for the issuance of the founder shares and a commitment from our sponsor to loan up to $300,000 to us to cover our expenses in connection with the Initial Public Offering.
We intend to use substantially all of the funds held in the trust account, including any amounts representing interest earned on the trust account (less permitted withdrawals and deferred underwriting commissions), to complete our business combination.
We will have available to us the proceeds held outside the trust account, as well as certain funds from loans from our sponsor, members of our management team or any of their affiliates. We will use these funds to primarily identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a business combination.
We do not believe we will need to raise additional funds following the Initial Public Offering in order to meet the expenditures required for operating our business prior to the completion of our business combination, other than funds available from loans from our sponsor, members of our management team or any of their affiliates. However, if our estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a business combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to the completion of our business combination. In order to fund working capital deficiencies or finance transaction costs in connection with an intended business combination, our sponsor, affiliates of our sponsor or our officers and directors may, but are not obligated to, loan us funds as may be required.
Off-Balance Sheet Financing Arrangements
We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2026. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
Contractual Obligations
As of September 30, 2026, we do not have any long-term debt, capital or operating lease obligations or long-term liabilities.
The underwriter is entitled to a deferred fee of $0.40 per share, or $3,000,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.
The Class B ordinary shares of the Company initially issued to the Sponsor (the “Class B Ordinary Shares” and together with the Class A Ordinary Shares, collectively, the “Ordinary Shares”), the Class A Ordinary Shares included in the Private Placement Shares, and any Class A Ordinary Shares that may be issued upon conversion of working capital loans (and any underlying securities) will be entitled to registration rights pursuant to a registration rights agreement entered into in connection with the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our completion of our business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.
16
Critical Accounting Policies and Estimates
In preparing these unaudited financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, actual results may differ from these estimates. We have not identified any critical accounting estimates.
Recent Accounting Pronouncements
Management does not believe that any other recently issued accounting pronouncements, if currently adopted, would have a material effect on our financial statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
As a smaller reporting company, we are not required to make disclosures under this Item.
Item 4. Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
Evaluation of Disclosure Controls and Procedures
In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. As required by Rule 13a-15(b) or Rule 15d-15(b) promulgated by the SEC under the Exchange Act, under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period ended September 30, 2026. Based on this evaluation, our principal executive officer and our principal financial and accounting officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the period ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
17
Item 6. Exhibits
| Exhibit No. |
Description | |
| 1.1 | Underwriting Agreement, by and between the Company and Jefferies LLC, dated October 13, 2026 (incorporated by reference to Exhibit 1.1 of the Company’s Current Report on Form 8-K (File No. 001-43504) filed on October 15, 2026). | |
| 3.1 | Amended and Restated Memorandum and Articles of Association of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K (File No. 001-43504) filed on October 15, 2026). | |
| 10.1 | Investment Management Trust Agreement, by and between the Company and Continental Stock Transfer & Trust Company, dated October 13, 2026 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K (File No. 001-43504) filed on October 15, 2026). | |
| 10.2 | Registration Rights Agreement, by and among the Company, the Sponsor, and certain officers and directors of the Company, dated October 13, 2026 (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K (File No. 001-43504) filed on October 15, 2026). | |
| 10.3 | Private Placement Shares Purchase Agreement, by and between the Company and the Sponsor, dated October 13, 2026 (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K (File No. 001-43504) filed on October 15, 2026). | |
| 10.4 | Forward Purchase Agreement, by and between the Company and Frazier Life Sciences Public Fund, L.P., dated October 13, 2026 (incorporated by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K (File No. 001-43504) filed on October 15, 2026). | |
| 10.5# | Form of Indemnity Agreement (incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-1 (File No. 333-299101) filed on September 24, 2026). | |
| 10.6 | Letter Agreement, by and among the Company, the Sponsor, and each director and officer of the Company, dated October 13, 2026 (incorporated by reference to Exhibit 10.6 of the Company’s Current Report on Form 8-K (File No. 001-43504) filed on October 15, 2026). | |
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act. | |
| 31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act. | |
| 32.1** | Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.INS* | Inline XBRL Instance Document. | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104* | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
| * | Filed herewith. |
| ** | The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. |
| # | Indicates a management contract or any compensatory plan, contract or arrangement. |
20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Frazier Life Sciences Acquisition Corp. II | ||||||
| Date: November 17, 2026 |
By: | /s/ Albert Cha | ||||
| Albert Cha, M.D., Ph.D. | ||||||
| Chief Executive Officer | ||||||
| (Principal Executive Officer) | ||||||
| Date: November 17, 2026 |
By: | /s/ Fran Adams | ||||
| Fran Adams | ||||||
| Chief Financial Officer | ||||||
| (Principal Financial and Accounting Officer) | ||||||
21